ReviewAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Ginkgo Biloba Extract in Ophthalmic and Systemic Disease, With a Focus on Normal-Tension Glaucoma.
Review in Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Article
- The strong correlation between visual function improvement and retinal microcirculation enhancement in glaucoma.Frontiers in medicine · 2025Article
- Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.Frontiers in medicine · 2025Review
- Glaucoma: Current and New Therapeutic Approaches.Biomedicines · 2024Review
- Retinal ischemia-reperfusion injury and pretreatment withInternational journal of ophthalmology · 2024Article
- Article
- Pharmaceutical Approaches to Normal Tension Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Real-time quality control of dripping pill's weight based on laser detection technology.Scientific reports · 2023Article
- Ginkgo biloba extracts improve choroidal circulation leading to suppression of myopia in mice.Scientific reports · 2023Article
- Herbal and Natural Treatments for the Management of the Glaucoma: An Update.BioMed research international · 2023Review
- Mitochondrial dysfunction in glaucomatous degeneration.International journal of ophthalmology · 2023Review
- Newer advances in medical management of glaucoma.Indian journal of ophthalmology · 2022Review
- Integrating network pharmacological and experimental models to investigate the therapeutic effects of baicalein in glaucoma.Chinese medicine · 2021Article
- Targeting the NLRP3 Inflammasome in Glaucoma.Biomolecules · 2021Review
- Ginkgo Biloba affects microvascular morphology: a prospective optical coherence tomography angiography pilot study.International ophthalmology · 2021Article
- Advances and Latest Developments in Ophthalmology and Visual Sciences.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a neurodegenerative eye disease that results in retinal ganglion cell loss and ultimately loss of vision. Elevated intraocular pressure (IOP) is the most common known risk factor for retinal ganglion cell damage and visual field loss, and the only modifiable risk factor proven to reduce the development and progression of glaucoma. This has greatly influenced our approach and assessment in terms of diagnosis and treatment. However, as many as ≥50% of patients with progressive vision loss from primary open angle glaucoma without IOP elevation (≤22 mm Hg) have been reported in the United States and Canada; 90% in Japan and 80% in Korea. Extensive research is currently underway to identify the etiology of risk factors for glaucoma other than or in addition to elevated IOP (so-called "normal-tension" glaucoma; NTG) and use this knowledge to expand available treatment options. Currently, Food and Drug Administration-approved medications for glaucoma exclusively target elevated IOP, suggesting the need for additional approaches to treatment options beyond the current scope as the definition of glaucoma changes to encompass cellular and molecular mechanisms. This review focuses on alternative medical approaches, specifically Ginkgo Biloba extract, as a potential treatment option for normal-tension glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.